NOAEL Studies
Cosmetic Ingredient
BHA (Butylated Hydroxyanisole) NOAEL Studies
INCI: BUTYLATED HYDROXYANISOLE
CAS: 25013-16-5
Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.
CIR_vision_codex 12 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| CIR_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | - | oral toxicity | {"citation":"125); 300); 210)","dose":"In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased...","effect":"contact and food packaging materials, including: as a pressure-sensitive adhesive (21CFR175.125), as an antioxidant in resinous and polymeric coatings (21CFR175.300), as a defoaming agent (21CFR176.210), and as a component of polyethylene film (21CFR179.45). In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased mortality and behavioral effects in rat pups at higher dose levels, and using an uncertainty factor of 100, the EFSA Panel on Food Additives and Nutrient Sources added to Food revised the acceptable daily intake (ADI) of BHA from 0.5 mg/kg bw/d to 1 mg/kg bw/d.11 TOXICOKINETIC STUDIES Dermal Absorption In Vitro The dermal absorption of BHA was measured in an in vitro preparation of human skin.12 After a 16-h continuous application of 0.07% BHA, approximately 30% of the applie...","page":6,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_001"} |
| CIR_vision_codex | NOAEL | =420 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk.","effect":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_002"} |
| CIR_vision_codex | NOAEL | =220 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"posed to 100 or 500 mg/kg BHA for 13 wk.","effect":"posed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_003"} |
| CIR_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | - | oral toxicity | {"citation":"125); 300); 210)","dose":"In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased...","effect":"contact and food packaging materials, including: as a pressure-sensitive adhesive (21CFR175.125), as an antioxidant in resinous and polymeric coatings (21CFR175.300), as a defoaming agent (21CFR176.210), and as a component of polyethylene film (21CFR179.45). In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased mortality and behavioral effects in rat pups at higher dose levels, and using an uncertainty factor of 100, the EFSA Panel on Food Additives and Nutrient Sources added to Food revised the acceptable daily intake (ADI) of BHA from 0.5 mg/kg bw/d to 1 mg/kg bw/d.11 TOXICOKINETIC STUDIES Dermal Absorption In Vitro The dermal absorption of BHA was measured in an in vitro preparation of human skin.12 After a 16-h continuous application of 0.07% BHA, approximately 30% of the applie...","page":6,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_001"} |
| CIR_vision_codex | NOAEL | =420 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk.","effect":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_002"} |
| CIR_vision_codex | NOAEL | =220 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"posed to 100 or 500 mg/kg BHA for 13 wk.","effect":"posed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_003"} |
| CIR_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | - | oral toxicity | {"citation":"125); 300); 210)","dose":"In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased...","effect":"contact and food packaging materials, including: as a pressure-sensitive adhesive (21CFR175.125), as an antioxidant in resinous and polymeric coatings (21CFR175.300), as a defoaming agent (21CFR176.210), and as a component of polyethylene film (21CFR179.45). In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased mortality and behavioral effects in rat pups at higher dose levels, and using an uncertainty factor of 100, the EFSA Panel on Food Additives and Nutrient Sources added to Food revised the acceptable daily intake (ADI) of BHA from 0.5 mg/kg bw/d to 1 mg/kg bw/d.11 TOXICOKINETIC STUDIES Dermal Absorption In Vitro The dermal absorption of BHA was measured in an in vitro preparation of human skin.12 After a 16-h continuous application of 0.07% BHA, approximately 30% of the applie...","page":6,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_001"} |
| CIR_vision_codex | NOAEL | =420 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk.","effect":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_002"} |
| CIR_vision_codex | NOAEL | =220 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"posed to 100 or 500 mg/kg BHA for 13 wk.","effect":"posed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_003"} |
| CIR_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | - | oral toxicity | {"citation":"125); 300); 210)","dose":"In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased...","effect":"contact and food packaging materials, including: as a pressure-sensitive adhesive (21CFR175.125), as an antioxidant in resinous and polymeric coatings (21CFR175.300), as a defoaming agent (21CFR176.210), and as a component of polyethylene film (21CFR179.45). In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased mortality and behavioral effects in rat pups at higher dose levels, and using an uncertainty factor of 100, the EFSA Panel on Food Additives and Nutrient Sources added to Food revised the acceptable daily intake (ADI) of BHA from 0.5 mg/kg bw/d to 1 mg/kg bw/d.11 TOXICOKINETIC STUDIES Dermal Absorption In Vitro The dermal absorption of BHA was measured in an in vitro preparation of human skin.12 After a 16-h continuous application of 0.07% BHA, approximately 30% of the applie...","page":6,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_001"} |
| CIR_vision_codex | NOAEL | =420 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk.","effect":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_002"} |
| CIR_vision_codex | NOAEL | =220 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | {"citation":"100; 500; 13","dose":"posed to 100 or 500 mg/kg BHA for 13 wk.","effect":"posed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","page":10,"pdf":"TR890.pdf","row_type":"noael_study","study_id":"TR890_noael_003"} |
COSMOS_DB 30 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| COSMOS_DB | NOAEL | 2000 | mg/kg bw/day | rat | oral | 90 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1000 | mg/kg bw/day | rat | oral | 32 day | Short Term Toxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1200 | mg/kg bw/day | hamster | oral | 140 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 250 | mg/kg bw/day | dog | oral | 180 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 125 | mg/kg bw/day | rat | oral | 728 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 500 | mg/kg bw/day | rat | oral | 728 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 750 | mg/kg bw/day | mouse | oral | 728 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 325 | mg/kg bw/day | dog | oral | 180 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 400 | mg/kg bw/day | swine | oral | 110 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 60 | mg/kg bw/day | dog | oral | 180 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 50 | mg/kg bw/day | swine | oral | 110 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 2400 | mg/kg bw/day | hamster | oral | 28 day | Short Term Toxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 100 | mg/kg bw/day | dog | oral | 365 day | Chronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 200 | mg/kg bw/day | rabbit | oral | 13 day | Developmental | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 225 | mg/kg bw/day | mouse | oral | 10 day | Developmental | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 120 | mg/kg bw/day | hamster | oral | 5 day | Developmental | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 662 | mg/kg bw/day | house shrew | oral | 560 day | Chronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 237 | mg/kg bw/day | dog | oral | 180 day | Subchronic | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 600 | mg/kg bw/day | rat | oral | 770 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 840 | mg/kg bw/day | syrian hamster | oral | 225 day | Special Toxicology Study | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1125 | mg/kg bw/day | mouse | oral | 10 day | Special Toxicology Study | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 375 | mg/kg bw/day | rat | oral | 14 day | Special Toxicology Study | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 150 | mg/kg bw/day | mouse | oral | 14 day | Special Toxicology Study | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1180 | mg/kg bw/day | rat | oral | 14 day | Short Term Toxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 300 | mg/kg bw/day | mouse | oral | 1 day | Short Term Toxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 974 | mg/kg bw/day | rat | oral | 728 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1375 | mg/kg bw/day | rat | oral | 728 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 956 | mg/kg bw/day | rat | oral | 728 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1041 | mg/kg bw/day | rat | oral | 728 day | Carcinogenicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1500 | mg/kg bw/day | mouse | oral | 21 day | Special Toxicology Study | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
California Proposition 65 6 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| California Proposition 65 | California Proposition 65 NSRL | AB4000 | ug/day | - | - | 1990-01-01 | No significant risk level | {"cancer_reproductive":"cancer","listed_date":"1990-01-01","listing_mechanism":"AB","madl":null,"nsrl":"4000","row_type":"nsrl","source_table":"prop65_listings"} |
| California Proposition 65 | California Proposition 65 NSRL | AB4000 | ug/day | - | - | 1990-01-01 | No significant risk level | {"cancer_reproductive":"cancer","listed_date":"1990-01-01","listing_mechanism":"AB","madl":null,"nsrl":"4000","row_type":"nsrl","source_table":"prop65_listings"} |
| California Proposition 65 | California Proposition 65 NSRL | AB4000 | ug/day | - | - | 1990-01-01 | No significant risk level | {"cancer_reproductive":"cancer","listed_date":"1990-01-01","listing_mechanism":"AB","madl":null,"nsrl":"4000","row_type":"nsrl","source_table":"prop65_listings"} |
| California Proposition 65 | California Proposition 65 listing | ABcancer | listing type | - | - | 1990-01-01 | California Proposition 65 listing | {"cancer_reproductive":"cancer","listed_date":"1990-01-01","listing_mechanism":"AB","madl":null,"nsrl":"4000","source_table":"prop65_listings"} |
| California Proposition 65 | California Proposition 65 listing | ABcancer | listing type | - | - | 1990-01-01 | California Proposition 65 listing | {"cancer_reproductive":"cancer","listed_date":"1990-01-01","listing_mechanism":"AB","madl":null,"nsrl":"4000","source_table":"prop65_listings"} |
| California Proposition 65 | California Proposition 65 listing | ABcancer | listing type | - | - | 1990-01-01 | California Proposition 65 listing | {"cancer_reproductive":"cancer","listed_date":"1990-01-01","listing_mechanism":"AB","madl":null,"nsrl":"4000","source_table":"prop65_listings"} |
EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx 2 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx | NOAEL | =100 | mg/kg bw/day | Rat | oral: unspecified | - | reproduction toxicity | EFSA ANS - 2011 - OutputID 488 - development - developmental - Scientific Opinion on the re-evaluation of butylated hydroxyanisole BHA (E 320) as a food additive - doi:10.2903/j.efsa.2011.2392 |
| EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx | NOAEL | =100 | mg/kg bw/day | Rat | oral: unspecified | - | reproduction toxicity | EFSA ANS - 2011 - OutputID 488 - development - developmental - Scientific Opinion on the re-evaluation of butylated hydroxyanisole BHA (E 320) as a food additive - doi:10.2903/j.efsa.2011.2392 |
EFSA_OpenFoodTox_EFSA_ReferenceValues.xlsx 2 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| EFSA_OpenFoodTox_EFSA_ReferenceValues.xlsx | ADI | =1 | mg/kg bw/day | Consumers | - | - | ADI | EFSA ANS - 2011 - OutputID 488 - Consumers - Scientific Opinion on the re-evaluation of butylated hydroxyanisole BHA (E 320) as a food additive - doi:10.2903/j.efsa.2011.2392 |
| EFSA_OpenFoodTox_EFSA_ReferenceValues.xlsx | ADI | =1 | mg/kg bw/day | Consumers | - | - | ADI | EFSA ANS - 2011 - OutputID 488 - Consumers - Scientific Opinion on the re-evaluation of butylated hydroxyanisole BHA (E 320) as a food additive - doi:10.2903/j.efsa.2011.2392 |
IARC Monographs 3 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| IARC Monographs | IARC carcinogenicity classification | 2B | IARC group | - | - | 1987 | IARC Monographs | {"additional_info":"volume_publication_year=1987","evaluation_year":1987,"source_table":"iarc_classifications","volume":"40, Sup 7"} |
| IARC Monographs | IARC carcinogenicity classification | 2B | IARC group | - | - | 1987 | IARC Monographs | {"additional_info":"volume_publication_year=1987","evaluation_year":1987,"source_table":"iarc_classifications","volume":"40, Sup 7"} |
| IARC Monographs | IARC carcinogenicity classification | 2B | IARC group | - | - | 1987 | IARC Monographs | {"additional_info":"volume_publication_year=1987","evaluation_year":1987,"source_table":"iarc_classifications","volume":"40, Sup 7"} |
NTP_ICE_cancer 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| NTP_ICE_cancer | IARC group | 2 | unitless | - | - | - | WOE; IARC Carcinogenicity | sheet=Data; excel_row=7430; Record_ID=cancer_837; Data_Type=WOE; Formulation_Name=Butylated hydroxyanisole; Mixture=Chemical; DTXSID=DTXSID7020215; Assay=IARC Carcinogenicity; Endpoint=IARC group; Response=2B; Response_Unit=Unitless; URL=http://publications.iarc.fr/58; http://publications.iarc.fr/139; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID7020215; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID7020215 |
NTP_ICE_endocrine 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| NTP_ICE_endocrine | NOEL | 500 | mg/kg bw/day | Rat | Oral | Treatment_Duration=10 days; Age_at_First_Dose=PND 51; Age_Ovariectomized_or_Castrated=PND 42; Time_Elapsed_Between_Surgery_and_Treatment=8 days; Time_Elapsed_Between_Last_Dose_and_Necropsy=18 to 36 hours; Number_of_Doses_Tested=8 | In Vivo; Hershberger-Agonist | sheet=Data_invivo; excel_row=1836; Record_ID=endocrine_invivo_788; Data_Type=In Vivo; Mixture=Chemical; DTXSID=DTXSID7020215; Assay=Hershberger-Agonist; Endpoint=NOEL; Response=500; Response_Unit=mg/kg/day; Species=Rat; Reported_Strain=Sprague-Dawley; Strain=Sprague-Dawley; Sex=Male (castrated); Route=Oral; Reference_Hormone=Testosterone propionate; Reference_Hormone_Dose=0.4; Reference_Hormone_Dose_Units=mg/kg/day; Reference_Hormone_Route=Subcutaneous; Additional_Information=Browne et al. 2018 unique record identifier 156; Reference=Kang et al. 2005; 16023279; 10.1016/j.tox.2005.05.027|Browne et al. 2018; 30205136; 10.1016/j.reprotox.2018.08.016; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID7020215; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID7020215 |
SCCS_vision_codex 28 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| SCCS_vision_codex | NOAEL | =50 | mg/kg bw/d | rat | oral | 4 weeks | repeated dose toxicity | {"citation":"Ref.: Miyakawa et al","dose":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx.","effect":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx. 1000 mg/kg body weight) in DMSO three times a week for 4 weeks. Repeated dermal dosing did not result in lethality or lung toxicity. Ref.: Miyakawa et al. 1986 SCCS conclusion on repeated dose toxicity After oral administration, the forestomach and liver were identified as target organs in oral repeat-dose studies in various animal species over different durations (see Annex I). The totality of these studies points to an NOAEL of 50 mg/kg bw/d based on liver effects. Systemic effects were not observed after repeated dermal application of BHA. Therefore, the SCCS will use 50 mg/kg bw/d as a point of departure (PoD) for MoS calculation. 3.4.5 Reproductive toxicity 3.4.5.1 Fertility and reproduction toxicity Fertility and toxicity to reproduction was investigated in a study similar to OECD TG 415. Groups of 12 male and 12 female Sprague-Dawley rats each received 0, 10, 100 or 500 mg BHA/kg bw/d (purity 99.9%) by gavage, dissolved in co","page":22,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_001"} |
| SCCS_vision_codex | NOAEL | =400 | mg/kg bw/day | rabbit | oral | 7 to day | reproductive toxicity | {"citation":"Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt p","dose":"There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters).","effect":"tokes and Scudder, 1974, quoted from EFSA, 2011 Doses of 0, 50, 200 or 400 mg BHA/kg bw/day were given orally by gavage to groups of pregnant New Zealand white rabbits from day 7 to day 18 of pregnancy. There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study. Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt pigs The pigs were maintained on the diet for three weeks and then artificially inseminated. Resulting numbers of pregnant animals were: 9 in the 0 mg/kg bw/day dose group, 11 in the 50 mg/kg bw/day dose group, 13 in the 200 mg/kg bw/day dose group and 1","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_002"} |
| SCCS_vision_codex | NOAEL | =200 | mg/kg bw/day | rat | - | developmental | reproductive toxicity | {"citation":"Ref.: Hansen et al","dose":"increased relative to the control at all dose levels tested.","effect":"increased relative to the control at all dose levels tested. There was no effect of BHA on the reproductive and developmental parameters. Anses noted that the histological picture of the thyroid indicated a reduced activity which was not confirmed by other parameters. In this study, it was not clear when the dosing period started (on the day of insemination or at the start of pregnancy). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study and that the NOAEL for maternal toxicity is 200 mg/kg bw/day. Ref.: Hansen et al., 1982, quoted from EFSA, 2011 and Anses, 2024 Anses (2024) mentions a further, poorly reported study (Clegg, 1965) administering BHA at 750 mg/kg bw/d BHA on GD 1-20 (n=32 females), BHA at 750 mg/kg bw/d for 70 days before pairing, continuing through pregnancy (n= 47 females) and a single administration of BHA on GD 9, 11 or 13 (n=111 females) to Albino rats. BHA also administered at 500 mg/kg bw/d Porton SPF rats for 7 weeks before pairing continuin","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_004"} |
| SCCS_vision_codex | NOAEL | =0.082 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"bw/d is used as a PoD for risk assessment. As explained in section 3.2.1 (Dermal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_006"} |
| SCCS_vision_codex | NOAEL | =0.079 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"rmal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_008"} |
| SCCS_vision_codex | NOAEL | =0.0029 | mg/kg bw/d | - | - | - | NOAEL study | {"dose":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_011"} |
| SCCS_vision_codex | NOAEL | =55 | mg/kg bw/d | rat | oral | 104 wk | NOAEL study | {"dose":"0.5, 50, 250 mg/kg bw/d), diet NOAEL:","effect":"pronounced hyperplasia: 1/14; hyperkeratosis: 1/14 close to esophagus: moderate hyperplasia: 1/14; hyperkeratosis 5/14 Species, Strain, number of animals per group Exposure Findings Reference Rat, Norway Hooded; Each 20 ♂, ♀ 8 mo 0; 0,001; 0,1; 0,5% BHA (ca. 0.5, 50, 250 mg/kg bw/d), diet NOAEL: 50 mg/kg bw/d 250 mg/kg bw/d: increased liver weight (investigated tissues: liver, kidney, spleen, testes) Brown et al., 1959 Rat, F344 50 ♂ 104 wk 0; 0,125; 0,25; 0,5; 1; 2% BHA (55, 110, 230, 428, 1323 mg/kg bw/d), diet NOAEL: 55 mg/kg bw/d from 110 mg/kg bw/d: decreased bw gain; forestomach hyperplasia at 230 and 428 mg/kg bw/d: hyperplasia of liver (not dose- dependent) Ito et al., 1986a Rat, F344 up to 31 ♂ 104 wk 0; 0,4% BHA (0 and ca. 200 mg/kg bw/d), diet At 200 mg/kg bw/d: Rel. liver and kidney weight increased Hirose et al., 1997 Rat, F344 27 ♂ 110 wk 0 and 12000mg BHA/kg diet (ca. 600 mg/kg bw/d) At 600 mg/kg bw/d: liver weight affected, liver effects, forestomach hyperplasia Williams et al., 1990b Rat, F344 50 ♂ 2 years 0, 1%","page":60,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_018"} |
| SCCS_vision_codex | NOAEL | =50 | mg/kg bw/d | rat | oral | 4 weeks | repeated dose toxicity | {"citation":"Ref.: Miyakawa et al","dose":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx.","effect":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx. 1000 mg/kg body weight) in DMSO three times a week for 4 weeks. Repeated dermal dosing did not result in lethality or lung toxicity. Ref.: Miyakawa et al. 1986 SCCS conclusion on repeated dose toxicity After oral administration, the forestomach and liver were identified as target organs in oral repeat-dose studies in various animal species over different durations (see Annex I). The totality of these studies points to an NOAEL of 50 mg/kg bw/d based on liver effects. Systemic effects were not observed after repeated dermal application of BHA. Therefore, the SCCS will use 50 mg/kg bw/d as a point of departure (PoD) for MoS calculation. 3.4.5 Reproductive toxicity 3.4.5.1 Fertility and reproduction toxicity Fertility and toxicity to reproduction was investigated in a study similar to OECD TG 415. Groups of 12 male and 12 female Sprague-Dawley rats each received 0, 10, 100 or 500 mg BHA/kg bw/d (purity 99.9%) by gavage, dissolved in co","page":22,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_001"} |
| SCCS_vision_codex | NOAEL | =400 | mg/kg bw/day | rabbit | oral | 7 to day | reproductive toxicity | {"citation":"Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt p","dose":"There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters).","effect":"tokes and Scudder, 1974, quoted from EFSA, 2011 Doses of 0, 50, 200 or 400 mg BHA/kg bw/day were given orally by gavage to groups of pregnant New Zealand white rabbits from day 7 to day 18 of pregnancy. There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study. Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt pigs The pigs were maintained on the diet for three weeks and then artificially inseminated. Resulting numbers of pregnant animals were: 9 in the 0 mg/kg bw/day dose group, 11 in the 50 mg/kg bw/day dose group, 13 in the 200 mg/kg bw/day dose group and 1","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_002"} |
| SCCS_vision_codex | NOAEL | =200 | mg/kg bw/day | rat | - | developmental | reproductive toxicity | {"citation":"Ref.: Hansen et al","dose":"increased relative to the control at all dose levels tested.","effect":"increased relative to the control at all dose levels tested. There was no effect of BHA on the reproductive and developmental parameters. Anses noted that the histological picture of the thyroid indicated a reduced activity which was not confirmed by other parameters. In this study, it was not clear when the dosing period started (on the day of insemination or at the start of pregnancy). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study and that the NOAEL for maternal toxicity is 200 mg/kg bw/day. Ref.: Hansen et al., 1982, quoted from EFSA, 2011 and Anses, 2024 Anses (2024) mentions a further, poorly reported study (Clegg, 1965) administering BHA at 750 mg/kg bw/d BHA on GD 1-20 (n=32 females), BHA at 750 mg/kg bw/d for 70 days before pairing, continuing through pregnancy (n= 47 females) and a single administration of BHA on GD 9, 11 or 13 (n=111 females) to Albino rats. BHA also administered at 500 mg/kg bw/d Porton SPF rats for 7 weeks before pairing continuin","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_004"} |
| SCCS_vision_codex | NOAEL | =0.082 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"bw/d is used as a PoD for risk assessment. As explained in section 3.2.1 (Dermal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_006"} |
| SCCS_vision_codex | NOAEL | =0.079 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"rmal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_008"} |
| SCCS_vision_codex | NOAEL | =0.0029 | mg/kg bw/d | - | - | - | NOAEL study | {"dose":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_011"} |
| SCCS_vision_codex | NOAEL | =50 | mg/kg bw/d | rat | oral | 4 weeks | repeated dose toxicity | {"citation":"Ref.: Miyakawa et al","dose":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx.","effect":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx. 1000 mg/kg body weight) in DMSO three times a week for 4 weeks. Repeated dermal dosing did not result in lethality or lung toxicity. Ref.: Miyakawa et al. 1986 SCCS conclusion on repeated dose toxicity After oral administration, the forestomach and liver were identified as target organs in oral repeat-dose studies in various animal species over different durations (see Annex I). The totality of these studies points to an NOAEL of 50 mg/kg bw/d based on liver effects. Systemic effects were not observed after repeated dermal application of BHA. Therefore, the SCCS will use 50 mg/kg bw/d as a point of departure (PoD) for MoS calculation. 3.4.5 Reproductive toxicity 3.4.5.1 Fertility and reproduction toxicity Fertility and toxicity to reproduction was investigated in a study similar to OECD TG 415. Groups of 12 male and 12 female Sprague-Dawley rats each received 0, 10, 100 or 500 mg BHA/kg bw/d (purity 99.9%) by gavage, dissolved in co","page":22,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_001"} |
| SCCS_vision_codex | NOAEL | =400 | mg/kg bw/day | rabbit | oral | 7 to day | reproductive toxicity | {"citation":"Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt p","dose":"There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters).","effect":"tokes and Scudder, 1974, quoted from EFSA, 2011 Doses of 0, 50, 200 or 400 mg BHA/kg bw/day were given orally by gavage to groups of pregnant New Zealand white rabbits from day 7 to day 18 of pregnancy. There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study. Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt pigs The pigs were maintained on the diet for three weeks and then artificially inseminated. Resulting numbers of pregnant animals were: 9 in the 0 mg/kg bw/day dose group, 11 in the 50 mg/kg bw/day dose group, 13 in the 200 mg/kg bw/day dose group and 1","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_002"} |
| SCCS_vision_codex | NOAEL | =200 | mg/kg bw/day | rat | - | developmental | reproductive toxicity | {"citation":"Ref.: Hansen et al","dose":"increased relative to the control at all dose levels tested.","effect":"increased relative to the control at all dose levels tested. There was no effect of BHA on the reproductive and developmental parameters. Anses noted that the histological picture of the thyroid indicated a reduced activity which was not confirmed by other parameters. In this study, it was not clear when the dosing period started (on the day of insemination or at the start of pregnancy). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study and that the NOAEL for maternal toxicity is 200 mg/kg bw/day. Ref.: Hansen et al., 1982, quoted from EFSA, 2011 and Anses, 2024 Anses (2024) mentions a further, poorly reported study (Clegg, 1965) administering BHA at 750 mg/kg bw/d BHA on GD 1-20 (n=32 females), BHA at 750 mg/kg bw/d for 70 days before pairing, continuing through pregnancy (n= 47 females) and a single administration of BHA on GD 9, 11 or 13 (n=111 females) to Albino rats. BHA also administered at 500 mg/kg bw/d Porton SPF rats for 7 weeks before pairing continuin","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_004"} |
| SCCS_vision_codex | NOAEL | =0.082 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"bw/d is used as a PoD for risk assessment. As explained in section 3.2.1 (Dermal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_006"} |
| SCCS_vision_codex | NOAEL | =0.079 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"rmal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_008"} |
| SCCS_vision_codex | NOAEL | =0.0029 | mg/kg bw/d | - | - | - | NOAEL study | {"dose":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_011"} |
| SCCS_vision_codex | NOAEL | =55 | mg/kg bw/d | rat | oral | 104 wk | NOAEL study | {"dose":"0.5, 50, 250 mg/kg bw/d), diet NOAEL:","effect":"pronounced hyperplasia: 1/14; hyperkeratosis: 1/14 close to esophagus: moderate hyperplasia: 1/14; hyperkeratosis 5/14 Species, Strain, number of animals per group Exposure Findings Reference Rat, Norway Hooded; Each 20 ♂, ♀ 8 mo 0; 0,001; 0,1; 0,5% BHA (ca. 0.5, 50, 250 mg/kg bw/d), diet NOAEL: 50 mg/kg bw/d 250 mg/kg bw/d: increased liver weight (investigated tissues: liver, kidney, spleen, testes) Brown et al., 1959 Rat, F344 50 ♂ 104 wk 0; 0,125; 0,25; 0,5; 1; 2% BHA (55, 110, 230, 428, 1323 mg/kg bw/d), diet NOAEL: 55 mg/kg bw/d from 110 mg/kg bw/d: decreased bw gain; forestomach hyperplasia at 230 and 428 mg/kg bw/d: hyperplasia of liver (not dose- dependent) Ito et al., 1986a Rat, F344 up to 31 ♂ 104 wk 0; 0,4% BHA (0 and ca. 200 mg/kg bw/d), diet At 200 mg/kg bw/d: Rel. liver and kidney weight increased Hirose et al., 1997 Rat, F344 27 ♂ 110 wk 0 and 12000mg BHA/kg diet (ca. 600 mg/kg bw/d) At 600 mg/kg bw/d: liver weight affected, liver effects, forestomach hyperplasia Williams et al., 1990b Rat, F344 50 ♂ 2 years 0, 1%","page":60,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_018"} |
| SCCS_vision_codex | NOAEL | =55 | mg/kg bw/d | rat | oral | 104 wk | NOAEL study | {"dose":"0.5, 50, 250 mg/kg bw/d), diet NOAEL:","effect":"pronounced hyperplasia: 1/14; hyperkeratosis: 1/14 close to esophagus: moderate hyperplasia: 1/14; hyperkeratosis 5/14 Species, Strain, number of animals per group Exposure Findings Reference Rat, Norway Hooded; Each 20 ♂, ♀ 8 mo 0; 0,001; 0,1; 0,5% BHA (ca. 0.5, 50, 250 mg/kg bw/d), diet NOAEL: 50 mg/kg bw/d 250 mg/kg bw/d: increased liver weight (investigated tissues: liver, kidney, spleen, testes) Brown et al., 1959 Rat, F344 50 ♂ 104 wk 0; 0,125; 0,25; 0,5; 1; 2% BHA (55, 110, 230, 428, 1323 mg/kg bw/d), diet NOAEL: 55 mg/kg bw/d from 110 mg/kg bw/d: decreased bw gain; forestomach hyperplasia at 230 and 428 mg/kg bw/d: hyperplasia of liver (not dose- dependent) Ito et al., 1986a Rat, F344 up to 31 ♂ 104 wk 0; 0,4% BHA (0 and ca. 200 mg/kg bw/d), diet At 200 mg/kg bw/d: Rel. liver and kidney weight increased Hirose et al., 1997 Rat, F344 27 ♂ 110 wk 0 and 12000mg BHA/kg diet (ca. 600 mg/kg bw/d) At 600 mg/kg bw/d: liver weight affected, liver effects, forestomach hyperplasia Williams et al., 1990b Rat, F344 50 ♂ 2 years 0, 1%","page":60,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_018"} |
| SCCS_vision_codex | NOAEL | =50 | mg/kg bw/d | rat | oral | 4 weeks | repeated dose toxicity | {"citation":"Ref.: Miyakawa et al","dose":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx.","effect":"0 female CD1 mice were epicutaneously administered 0.1 ml of a solution of 30 mg BHA (approx. 1000 mg/kg body weight) in DMSO three times a week for 4 weeks. Repeated dermal dosing did not result in lethality or lung toxicity. Ref.: Miyakawa et al. 1986 SCCS conclusion on repeated dose toxicity After oral administration, the forestomach and liver were identified as target organs in oral repeat-dose studies in various animal species over different durations (see Annex I). The totality of these studies points to an NOAEL of 50 mg/kg bw/d based on liver effects. Systemic effects were not observed after repeated dermal application of BHA. Therefore, the SCCS will use 50 mg/kg bw/d as a point of departure (PoD) for MoS calculation. 3.4.5 Reproductive toxicity 3.4.5.1 Fertility and reproduction toxicity Fertility and toxicity to reproduction was investigated in a study similar to OECD TG 415. Groups of 12 male and 12 female Sprague-Dawley rats each received 0, 10, 100 or 500 mg BHA/kg bw/d (purity 99.9%) by gavage, dissolved in co","page":22,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_001"} |
| SCCS_vision_codex | NOAEL | =400 | mg/kg bw/day | rabbit | oral | 7 to day | reproductive toxicity | {"citation":"Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt p","dose":"There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters).","effect":"tokes and Scudder, 1974, quoted from EFSA, 2011 Doses of 0, 50, 200 or 400 mg BHA/kg bw/day were given orally by gavage to groups of pregnant New Zealand white rabbits from day 7 to day 18 of pregnancy. There were no observed differences between the treated groups and controls in the parameters measured (body weight, incidence of soft tissue or skeletal abnormalities, number of foetuses born dead or alive, number of corpora lutea and implantations, general reproductive parameters). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study. Ref.: Hansen and Meyer (1978), quoted from EFSA, 2011 A diet containing the equivalent of 0, 50, 200, or 400 mg BHA/kg bw/day was given to groups of 10 young adult Danish Landrace gilt pigs The pigs were maintained on the diet for three weeks and then artificially inseminated. Resulting numbers of pregnant animals were: 9 in the 0 mg/kg bw/day dose group, 11 in the 50 mg/kg bw/day dose group, 13 in the 200 mg/kg bw/day dose group and 1","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_002"} |
| SCCS_vision_codex | NOAEL | =200 | mg/kg bw/day | rat | - | developmental | reproductive toxicity | {"citation":"Ref.: Hansen et al","dose":"increased relative to the control at all dose levels tested.","effect":"increased relative to the control at all dose levels tested. There was no effect of BHA on the reproductive and developmental parameters. Anses noted that the histological picture of the thyroid indicated a reduced activity which was not confirmed by other parameters. In this study, it was not clear when the dosing period started (on the day of insemination or at the start of pregnancy). The EFSA Panel concluded that a NOAEL for developmental toxicity of 400 mg/kg bw/day can be derived from this study and that the NOAEL for maternal toxicity is 200 mg/kg bw/day. Ref.: Hansen et al., 1982, quoted from EFSA, 2011 and Anses, 2024 Anses (2024) mentions a further, poorly reported study (Clegg, 1965) administering BHA at 750 mg/kg bw/d BHA on GD 1-20 (n=32 females), BHA at 750 mg/kg bw/d for 70 days before pairing, continuing through pregnancy (n= 47 females) and a single administration of BHA on GD 9, 11 or 13 (n=111 females) to Albino rats. BHA also administered at 500 mg/kg bw/d Porton SPF rats for 7 weeks before pairing continuin","page":24,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_004"} |
| SCCS_vision_codex | NOAEL | =0.082 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"bw/d is used as a PoD for risk assessment. As explained in section 3.2.1 (Dermal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_006"} |
| SCCS_vision_codex | NOAEL | =0.079 | mg/kg bw/d | - | oral | - | dermal absorption | {"dose":"No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"rmal/percutaneous absorption), a default of 50 % is used as dermal absorption percentage. No correction is made for oral absorption (see section 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_008"} |
| SCCS_vision_codex | NOAEL | =0.0029 | mg/kg bw/d | - | - | - | NOAEL study | {"dose":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated.","effect":"n 3.2.) As explained in section 3.3.2, SEDs of 0.082 mg/kg bw/d (for leave-on and rinse-off products combined), 0.0029 mg/kg bw/d for rinse-off products and 0.079 mg/kg bw/d for leave-on products were calculated. Safety calculations: Leave-on and rinse-off products combined: SED: 0.082 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 610 Leave-on products alone: SED: 0.079 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 632 Rinse-off products alone: SED: 0.0029 mg/kg bw/d NOAEL (not adjusted): 50 mg/kg bw/d Margin of Safety (NOAEL/SED) adjusted NOAEL/SED = 17251","page":45,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_011"} |
| SCCS_vision_codex | NOAEL | =55 | mg/kg bw/d | rat | oral | 104 wk | NOAEL study | {"dose":"0.5, 50, 250 mg/kg bw/d), diet NOAEL:","effect":"pronounced hyperplasia: 1/14; hyperkeratosis: 1/14 close to esophagus: moderate hyperplasia: 1/14; hyperkeratosis 5/14 Species, Strain, number of animals per group Exposure Findings Reference Rat, Norway Hooded; Each 20 ♂, ♀ 8 mo 0; 0,001; 0,1; 0,5% BHA (ca. 0.5, 50, 250 mg/kg bw/d), diet NOAEL: 50 mg/kg bw/d 250 mg/kg bw/d: increased liver weight (investigated tissues: liver, kidney, spleen, testes) Brown et al., 1959 Rat, F344 50 ♂ 104 wk 0; 0,125; 0,25; 0,5; 1; 2% BHA (55, 110, 230, 428, 1323 mg/kg bw/d), diet NOAEL: 55 mg/kg bw/d from 110 mg/kg bw/d: decreased bw gain; forestomach hyperplasia at 230 and 428 mg/kg bw/d: hyperplasia of liver (not dose- dependent) Ito et al., 1986a Rat, F344 up to 31 ♂ 104 wk 0; 0,4% BHA (0 and ca. 200 mg/kg bw/d), diet At 200 mg/kg bw/d: Rel. liver and kidney weight increased Hirose et al., 1997 Rat, F344 27 ♂ 110 wk 0 and 12000mg BHA/kg diet (ca. 600 mg/kg bw/d) At 600 mg/kg bw/d: liver weight affected, liver effects, forestomach hyperplasia Williams et al., 1990b Rat, F344 50 ♂ 2 years 0, 1%","page":60,"pdf":"sccs_o_306.pdf","row_type":"noael_study","study_id":"sccs_o_306_noael_018"} |
ToxValDB_ECOTOX 4 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| ToxValDB_ECOTOX | LOEL | =500 | mg/kg bw/day | Mouse | oral | acute; 1 days | acute | LONG_REF=Mutat. Res.519(1/2): 103-119 Sasaki,Y.F., S. Kawaguchi, A. Kamaya, M. Ohshita, K. Kabasawa, K. Iwama, K. Taniguchi, and S. Tsuda The Comet Assay with 8 Mouse Organs: Results with 39 Currently Used Food Additives 2002; TITLE=The Comet Assay with 8 Mouse Organs: Results with 39 Currently Used Food Additives; AUTHOR=Sasaki,Y.F., S. Kawaguchi, A. Kamaya, M. Ohshita, K. Kabasawa, K. Iwama, K. Taniguchi, and S. Tsuda; DOI=10.1016/s1383-5718(02)00128-6; QUALITY=Control type: Concurrent control; EXTERNAL_SOURCE_ID=75840; EXTERNAL_SOURCE_ID_DESC=ECOTOX Reference Number; STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/6759bce8e4b0a7c65d37bc5f; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://cfpub.epa.gov/ecotox/; YEAR=2002; ORIGINAL_YEAR=2002; TOXICOLOGICAL_EFFECT=Genetics: Damage; TOXICOLOGICAL_EFFECT_CATEGORY=other; STUDY_GROUP=ECOTOX_dup_EPA ORD_15607592_15607593:M:--; QC_CATEGORY=Data source QC'd by data provider prior to ECOTOX import; QC_STATUS=not determined; SOURCE_HASH=0a9b557befd14cc3f3710b072e45e203 |
| ToxValDB_ECOTOX | NOEL | =0.75 | % w/v | Mouse | oral | short-term; 8.0833 days | short-term | LONG_REF=Toxicol. Appl. Pharmacol.87(3): 389-392 Ketterman,A.J., S.M. Pond, and C.E. Becker The Effects of Differential Induction of Cytochrome P-450, Carboxylesterase and Glutathione S-Transferase Activities on Malathion Toxicity in Mice 1987; TITLE=The Effects of Differential Induction of Cytochrome P-450, Carboxylesterase and Glutathione S-Transferase Activities on Malathion Toxicity in Mice; AUTHOR=Ketterman,A.J., S.M. Pond, and C.E. Becker; DOI=10.1016/0041-008x(87)90243-2; QUALITY=Control type: Concurrent control; EXTERNAL_SOURCE_ID=88919; EXTERNAL_SOURCE_ID_DESC=ECOTOX Reference Number; STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/6759bce8e4b0a7c65d37bc5f; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://cfpub.epa.gov/ecotox/; YEAR=1987; ORIGINAL_YEAR=1987; TOXICOLOGICAL_EFFECT=Enzyme(s): Acetylcholinesterase|Enzyme(s): Cytochrome P-450|Enzyme(s): Malathion carboxylesterase; TOXICOLOGICAL_EFFECT_CATEGORY=enzyme activity|neurotransmitter; STUDY_GROUP=ECOTOX_dup_EPA ORD_15595130_15596728:M:--; QC_CATEGORY=Data source QC'd by data provider prior to ECOTOX import; QC_STATUS=not determined; SOURCE_HASH=290206b7fb741beb64a2e9506b0c1ba8 |
| ToxValDB_ECOTOX | NOEL | =2 | % | Rat | oral | subchronic; 56 days | subchronic | LONG_REF=Toxicol. Appl. Pharmacol.99(1): 37-49 Shibata,M.A., M. Yamada, H. Tanaka, M. Kagawa, and S. Fukushima Changes in Urine Composition, Bladder Epithelial Morphology, and DNA Synthesis in Male F344 Rats in Response to Ingestion of Bladder Tumor Promoters 1989; TITLE=Changes in Urine Composition, Bladder Epithelial Morphology, and DNA Synthesis in Male F344 Rats in Response to Ingestion of Bladder Tumor Promoters; AUTHOR=Shibata,M.A., M. Yamada, H. Tanaka, M. Kagawa, and S. Fukushima; DOI=10.1016/0041-008x(89)90109-9; QUALITY=Control type: Multiple entries; EXTERNAL_SOURCE_ID=106692; EXTERNAL_SOURCE_ID_DESC=ECOTOX Reference Number; STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/6759bce8e4b0a7c65d37bc5f; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://cfpub.epa.gov/ecotox/; YEAR=1989; ORIGINAL_YEAR=1989; TOXICOLOGICAL_EFFECT=Biochemistry: Phosphorus content|Physiology: Osmolality; TOXICOLOGICAL_EFFECT_CATEGORY=clinical chemistry|urinalysis; STUDY_GROUP=ECOTOX_dup_EPA ORD_15606152_15606153:M:--; QC_CATEGORY=Data source QC'd by data provider prior to ECOTOX import; QC_STATUS=not determined; SOURCE_HASH=9e32b962490f3ab16295ff87c645719c |
| ToxValDB_ECOTOX | NOEL | =100 | mg/kg bw/day | Mouse | oral | acute; 1 days | acute | LONG_REF=Mutat. Res.519(1/2): 103-119 Sasaki,Y.F., S. Kawaguchi, A. Kamaya, M. Ohshita, K. Kabasawa, K. Iwama, K. Taniguchi, and S. Tsuda The Comet Assay with 8 Mouse Organs: Results with 39 Currently Used Food Additives 2002; TITLE=The Comet Assay with 8 Mouse Organs: Results with 39 Currently Used Food Additives; AUTHOR=Sasaki,Y.F., S. Kawaguchi, A. Kamaya, M. Ohshita, K. Kabasawa, K. Iwama, K. Taniguchi, and S. Tsuda; DOI=10.1016/s1383-5718(02)00128-6; QUALITY=Control type: Concurrent control; EXTERNAL_SOURCE_ID=75840; EXTERNAL_SOURCE_ID_DESC=ECOTOX Reference Number; STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/6759bce8e4b0a7c65d37bc5f; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://cfpub.epa.gov/ecotox/; YEAR=2002; ORIGINAL_YEAR=2002; TOXICOLOGICAL_EFFECT=Genetics: Damage; TOXICOLOGICAL_EFFECT_CATEGORY=other; STUDY_GROUP=ECOTOX_dup_EPA ORD_15607592_15607593:M:--; QC_CATEGORY=Data source QC'd by data provider prior to ECOTOX import; QC_STATUS=not determined; SOURCE_HASH=37769999adf9ad5df3f5d820fc2dd8ba |
ToxValDB_EFSA 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| ToxValDB_EFSA | NOAEL | =100 | mg/kg bw/day | Rat | oral | - | developmental | LONG_REF=EFSA ANS (2011). Scientific Opinion on the re-evaluation of butylated hydroxyanisole BHA (E 320) as a food additive. doi:10.2903/j.efsa.2011.2392.; TITLE=Scientific Opinion on the re-evaluation of butylated hydroxyanisole BHA (E 320) as a food additive; AUTHOR=EFSA ANS; DOI=doi:10.2903/j.efsa.2011.2392; STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/65201d30e4b0f0a60ddd1165; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://zenodo.org/record/5076033#.Y9fEoXbMI2z; YEAR=2011; ORIGINAL_YEAR=2011; TOXICOLOGICAL_EFFECT=development; TOXICOLOGICAL_EFFECT_CATEGORY=development; STUDY_GROUP=EFSA_dup_-_15614341_15614342_15614343:-:--; QC_CATEGORY=Programmatically extracted from structured data source; Source overall passed QC, but this record was not manually checked; QC_STATUS=not determined; SOURCE_HASH=ToxValhc_f4860a914ce41c83c6db2710fbad625e |
ToxValDB_WHO_JECFA_ADI 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| ToxValDB_WHO_JECFA_ADI | ADI | <=0.5 | mg/kg | Human | oral | - | Toxicity Value | STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/650afb36e4b0d99f5a87a669; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://apps.who.int/food-additives-contaminants-jecfa-database/; SUBSOURCE_URL=https://apps.who.int/food-additives-contaminants-jecfa-database/Home/Chemical/1910; YEAR=1988; ORIGINAL_YEAR=1988; STUDY_GROUP=WHO JECFA ADI:15715345:-:--; QC_CATEGORY=Programmatically extracted from structured data source; Source overall passed QC, but this record was not manually checked; QC_STATUS=not determined; SOURCE_HASH=ToxValhc_40ef5fb290354b51ced1628598a40bd2 |
UnifiedCodex:CIR:beta.noael_studies 3 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| UnifiedCodex:CIR:beta.noael_studies | oral toxicity | 100 | mg/kg bw/d | rat | oral | - | oral toxicity | SOURCE_SUBDIR=TR890; REPORT_TITLE=Amended Safety Assessment of BHA as Used in Cosmetics Status: Tentative Amended Report for Public Comment Last Panel Review:; OPINION_NUMBER=TR890; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=Review 1620; VALUE_TEXT=100; DOSE=In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased...; EFFECT=contact and food packaging materials, including: as a pressure-sensitive adhesive (21CFR175.125), as an antioxidant in resinous and polymeric coatings (21CFR175.300), as a defoaming agent (21CFR176.210), and as a component of polyethylene film (21CFR179.45). In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased mortality and behavioral effects in rat pups at higher dose levels, and using an uncertainty factor of 100, the EFSA Panel on Food Additives and Nutrient Sources added to Food revised the acceptable daily intake (ADI) of BHA from 0.5 mg/kg bw/d to 1 mg/kg bw/d.11 TOXICOKINETIC STUDIES Dermal Absorption In Vitro The dermal absorption of BHA was measured in an in vitro preparation of human skin.12 After a 16-h continuous application of 0.07% BHA, approximately 30% of the applie...; CITATION=125); 300); 210); CITATION_NUMBERS=[125,300,210]; REFERENCE=125); 300); 210); DETAILS_JSON={"cas_number":"25013-16-5","citation":"125); 300); 210)","dose":"In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased...","duration":"","effect":"contact and food packaging materials, including: as a pressure-sensitive adhesive (21CFR175.125), as an antioxidant in resinous and polymeric coatings (21CFR175.300), as a defoaming agent (21CFR176.210), and as a component of polyethylene film (21CFR179.45). In 2019, the European Food Safety Authority (EFSA) determined that the maximum authorized BHA content in animal feed (all animals, except cats), either alone, or in combination with butylated hydroxytoluene and/or ethoxyquin is 150 mg/kg.10 In 2011, based on a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg bw/d BHA for growth retardation, increased mortality and behavioral effects in rat pups at higher dose levels, and using an uncertainty factor of 100, the EFSA Panel on Food Additives and Nutrient Sources added to Food revised the acceptable daily intake (ADI) of BHA from 0.5 mg/kg bw/d to 1 mg/kg bw/d.11 TOXICOKINETIC STUDIES Dermal Absorption In Vitro The dermal absorption of BHA was measured in an in vitro preparation of human skin.12 After a 16-h continuous application of 0.07% BHA, approximately 30% of the applie...","endpoint":"oral toxicity","ingredient":"BHA","loael_value":"","noael_unit":"mg/kg bw/d","noael_value":"100","page":6,"route":"oral","species":"rat","study_id":"TR890_noael_001"} |
| UnifiedCodex:CIR:beta.noael_studies | reproductive toxicity | 420 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | SOURCE_SUBDIR=TR890; REPORT_TITLE=Amended Safety Assessment of BHA as Used in Cosmetics Status: Tentative Amended Report for Public Comment Last Panel Review:; OPINION_NUMBER=TR890; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=Review 1620; VALUE_TEXT=420; DOSE=een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk.; LOAEL_VALUE=420 mg/kg/d; EFFECT=een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.; CITATION=100; 500; 13; CITATION_NUMBERS=[100,500,13]; REFERENCE=100; 500; 13; DETAILS_JSON={"cas_number":"25013-16-5","citation":"100; 500; 13","dose":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk.","duration":"13 wk","effect":"een, vagina, testes, and ventral prostate were decreased in the F1 (filial) generation rats exposed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","endpoint":"reproductive toxicity","ingredient":"BHA","loael_value":"420 mg/kg/d","noael_unit":"mg/kg/d","noael_value":"420","page":10,"route":"oral","species":"rat","study_id":"TR890_noael_002"} |
| UnifiedCodex:CIR:beta.noael_studies | reproductive toxicity | 220 | mg/kg/d | rat | oral | 13 wk | reproductive toxicity | SOURCE_SUBDIR=TR890; REPORT_TITLE=Amended Safety Assessment of BHA as Used in Cosmetics Status: Tentative Amended Report for Public Comment Last Panel Review:; OPINION_NUMBER=TR890; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=Review 1620; VALUE_TEXT=220; DOSE=posed to 100 or 500 mg/kg BHA for 13 wk.; LOAEL_VALUE=420 mg/kg/d; EFFECT=posed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.; CITATION=100; 500; 13; CITATION_NUMBERS=[100,500,13]; REFERENCE=100; 500; 13; DETAILS_JSON={"cas_number":"25013-16-5","citation":"100; 500; 13","dose":"posed to 100 or 500 mg/kg BHA for 13 wk.","duration":"13 wk","effect":"posed to 100 or 500 mg/kg BHA for 13 wk. Additionally, reduced velocity of sperm motion and number, lowered serum levels of thyroxine and testosterone, slightly shortened estrous cycle length, and effects in the follicular epithelial cells of the thyroid were observed in F1 rats exposed to 500 mg/kg BHA. In another reproductive toxicity study, male and female rats received 0, 110, 220, or 420 mg/kg/d BHA, in the diet; the NOAEL for maternal toxicity was determined to be 420 mg/kg/d for.15 For offspring toxicity, a NOAEL of 220 mg/kg/d BHA and a LOAEL of 420 mg/kg/d BHA was established, based on the reduced weight of progeny during lactation and increasing peri-weaning mortality.","endpoint":"reproductive toxicity","ingredient":"BHA","loael_value":"420 mg/kg/d","noael_unit":"mg/kg/d","noael_value":"220","page":10,"route":"oral","species":"rat","study_id":"TR890_noael_003"} |
openFDA substances 4 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| openFDA substances | FDA UNII substance identifier | REK4960K2U | UNII | - | - | - | mixture | {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"mixture","unii_code":"REK4960K2U"} |
| openFDA substances | FDA UNII substance identifier | REK4960K2U | UNII | - | - | - | mixture | {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"mixture","unii_code":"REK4960K2U"} |
| openFDA substances | FDA UNII substance identifier | REK4960K2U | UNII | - | - | - | mixture | {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"mixture","unii_code":"REK4960K2U"} |
| openFDA substances | FDA UNII substance identifier | REK4960K2U | UNII | - | - | - | mixture | {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"mixture","unii_code":"REK4960K2U"} |